This document discusses different types of epidemiological studies, including observational analytical studies like cohort and case-control studies, as well as interventional experimental studies. Cohort studies follow groups over time from exposure to disease outcome, while case-control studies compare cases and controls retrospectively from disease outcome back to exposure. Experimental studies actively manipulate variables to evaluate new drugs, technologies, programs, and more. Both observational and experimental studies have advantages like establishing causality, but also disadvantages like costs or ethical concerns.
A vaccine is a biological preparation that improves immunity to a particular Disease.
No vaccine is completely safe or completely effective, while all known vaccine adverse events are minor and self limited, some vaccine have been associated with rare but serious health effects.
A vaccine is a biological preparation that improves immunity to a particular Disease.
No vaccine is completely safe or completely effective, while all known vaccine adverse events are minor and self limited, some vaccine have been associated with rare but serious health effects.
Bias, confounding and causality in p'coepidemiological researchsamthamby79
A brief description of three issues (Bias, Confounding and Causality) commonly encountered while performing pharmacoepidemiological research. A big THANK YOU to Mr. Strom and Mr. Kimmel.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
A cross-sectional study is a descriptive study in which disease and exposure status are measured simultaneously in a given population.
It measures
the prevalence of health outcomes(also called prevalence study)
or determinants of health,
or both,
In a population at a point in time or over a short period.
When the investigator draws a sample out of the study population of interest and examines all the subjects to detect
those having the disease/outcome
and those not having this disease/outcome of interest.
At the same time, finds out whether or not they have the presence of
the suspected cause (exposure)
(or give a History of such exposure in the past),
is called the Cross-sectional analytic study.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
Bias, confounding and causality in p'coepidemiological researchsamthamby79
A brief description of three issues (Bias, Confounding and Causality) commonly encountered while performing pharmacoepidemiological research. A big THANK YOU to Mr. Strom and Mr. Kimmel.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
A cross-sectional study is a descriptive study in which disease and exposure status are measured simultaneously in a given population.
It measures
the prevalence of health outcomes(also called prevalence study)
or determinants of health,
or both,
In a population at a point in time or over a short period.
When the investigator draws a sample out of the study population of interest and examines all the subjects to detect
those having the disease/outcome
and those not having this disease/outcome of interest.
At the same time, finds out whether or not they have the presence of
the suspected cause (exposure)
(or give a History of such exposure in the past),
is called the Cross-sectional analytic study.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
what is patient counselling, objective of patient counselling, steps in patient counselling, patient counselling contents, process, conclusion, communicative skill for effective counselling, verbal communication, non verbal communications
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
2. Observational Analytical studies -
• Cohort study
• Case control study
Experimental studies -
• Clinical and preventive trials
• Pre, quasi and true experimental studies
3. Concept of
cohort
The word cohort is derived from the Latin “cohorts”
meaning an enclosure, company, or crowd. In Roman
times a cohort was a body of 300–600 infantry.
In epidemiological terms the cohort is a group of
people with something in common, usually an
exposure or involvement in a defined population
group.
4. Definitio
n
Cohort study is a type of analytical
study which is undertaken to obtain
additional evidence to refute or support
existence of association between
suspected cause and diseases.
• Other names of cohort study are
Longitudinal study, Incidence study and
forward looking study
5. Features of
cohort
studies
Cohorts are identified prior to
appearance of disease under
investigation
• The study groups are observed over
a period of time to determine the
frequency of disease among them
• The study proceeds from cause to
effects
6. Indications for cohort study
• There is good evidence of an association between exposure and disease,
from other studies.
• Exposure is rare.
• Attrition of study population can be minimized.
• Sufficient fund is available.
7. Consideration
during
selection of
Cohort
• The cohort must
be free from
disease under
study.
• Insofar as the
knowledge permits,
both the groups
should be equally
susceptible to
disease under
study.
• Both the groups
must be
comparable in
respect of all
variable which
influence the
occurrence of
disease
• Diagnostic and
eligibility criteria of
the disease must
be defined
beforehand.
8. Types of cohort study
• Prospective
study
•
Retrospective
cohort study
• Ambi-
directional
cohort study
9. Steps of
Cohort Study
1 -Selection
of study
population
2 -Obtaining
Data on
exposure
3 -Selection
of comparison
group
4 -Follow up
5 -Analysis
10. Advantage of
Cohort
Studies
• Multiple outcomes can be measured for any one exposure.
• Temporality can be established
• Suitable for new/unusual or rare exposures.
• Can measure incidence and prevalence
• Provide direct estimate of risk.
• Less chance of bias.
• Strongest analytical capacity (among analytical studies)
11. Disadvantag
e of Cohort
Studies
• Costly and time consuming.
• Large sample size is required.
• High chances of drop out.
• Prone to confounding.
• Being in the study may alter participant's
behavior.
• Not suitable for a rare disease.
• Classification of individuals (exposure or
outcome status) can be affected by changes in
diagnostic procedures.
• May arise ethical issues.
12. Case Control
Study
A study that compares two groups of people: those with the disease or condition
under study (cases) and a very similar group of people who do not have the disease
or condition (controls).
A case control study involves two populations – cases and controls and has three
distinct features :
• Both exposure and outcome have occurred before the start of the study.
• The study proceeds backwards from effect to cause.
• It uses a control or comparison group to support or refute an inference.
Case : A person in the population or study group identified as having the particular
disease, health disorder or condition under investigation.
Control: Person or persons in a comparison group that differs, in disease
experience (or other health related outcome) in not having the outcome being
studied.
13. Design of
Case Control
Study
The investigator selects cases with the
disease and appropriate controls without
the disease and obtains data regarding
past exposure to possible etiologic factors
in both groups. The investigator then
compares the frequency of exposure of the
two groups.
14. Interventional Studies
Interventional study also called Experimental study Investigators intervene in the natural
history by actively altering one of the variables and then making inference on the relationship
between variables based on the outcomes.
15. Experimental
study can
evaluate
• New drugs and new treatment of
diseases
• New medical and health care technology
• New methods of primary prevention
• New program for screening
• New ways of organizing and delivering
health services
• New community health programs
• New behavioral intervention programs
16. Types
• Pre-experimental: There is
manipulation of variable but does not
have control group.
• Quasi-experimental study: There is
manipulation of certain variable and has
control group but no randomization.
• True experimental design: Three
features: Randomization, manipulation
and control
17. Types of
Trials
Therapeutic (clinical Trial)
• Study population – Patients with disease
• Objectives
– Cure patients
– Prevent recurrence of disease/risk of death
Preventive (community Trial)
• Study Population – Population at risk
• Objectives – Reduce the risk of developing
disease
18. Advantages of Experimental study
◦ 1. Best Results
◦ 2. Determine Cause and Effect
◦ 3. Variables Are Controlled
◦ 4. Easily Replicated
Disadvantages of experimental study
◦ 1. Costly
◦ 2. Methodologically demanding
◦ 3. Not Real Life Situations
◦ 4. Human Errors